Siamab Therapeutics Inc

Elevian, Inc. is a biotechnology company based in Newton, MA, dedicated to developing innovative medicines that promote recovery and regeneration. Their lead program focuses on the development of a recombinant protein for the treatment of stroke, aiming to provide viable treatments for stroke patients in the days following the event, where currently there are no available options. Elevian's medicines have the potential to not only treat stroke but also prevent and address various aging-associated diseases. With stroke being a leading cause of long-term disability and the second leading cause of death globally, Elevian's research and development efforts are centered around promoting regeneration and recovery in the hours and days following a stroke. Their recombinant protein, rGDF11, has shown promising results in facilitating motor function recovery in animal models of both ischemic and hemorrhagic stroke. Additionally, rGDF11 has demonstrated potential in promoting recovery and regeneration in various preclinical models of aging-related diseases, including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.Generated from the website

Abcuro, Inc. is a clinical-stage biotechnology company based in Newton, Massachusetts, focused on developing innovative therapies for autoimmune diseases and cancer by precisely modulating highly cytotoxic T cells. The company is known for its investigational monoclonal antibody, Ulviprubart, which selectively targets and depletes these T cells implicated in tissue damage associated with various autoimmune disorders. Recent leadership enhancements, such as the appointment of Courtney Cupples as Chief Commercial Officer, underscore Abcuro's commitment to advancing its therapeutic pipeline and expanding its market reach in the field of rare diseases. Their ongoing research aims to improve treatment outcomes for conditions like Inclusion Body Myositis, where highly cytotoxic T cells play a significant role in muscle degeneration. Generated from the website

BioSensics LLC is a global leader in the development of wearable sensors and digital platforms for clinical trials, patient monitoring, and health assessment, offering advanced technologies for effective measurement and analysis of digital biomarkers and health data. With their turnkey products, including wearable sensors, mobile health applications, and medical devices, BioSensics revolutionizes clinical trials and research, patient monitoring, and health assessment, providing comprehensive operational and technical services for these purposes.Generated from the website